The Incidence of Hyperuricemia and Correlated Factors in Middle-Aged Japanese Men

Noriyuki NAKANISHI; Koji NAKAMURA; Kenji SUZUKI; Kozo TATARA

doi:10.1539/joh.42.1

Noriyuki NAKANISHI, Koji NAKAMURA, Kenji SUZUKI, Kozo TATARA

著者情報

キーワード: Incidence of hyperuricemia, Risk factors, Longitudinal study, Japanese men, Middle age

ジャーナルフリー

2000 年 42 巻 1 号 p. 1-7

DOI https://doi.org/10.1539/joh.42.1

詳細

Published: 2000 Received: 1999/04/26 Available on J-STAGE: 2006/04/07 Accepted: 1999/08/02 Advance online publication: - Revised: -
訂正情報
訂正日: 2006/04/07 訂正理由: - 訂正箇所: 引用文献情報訂正内容: Wrong : 1) Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia: risks and consequences in the Normative Aging Study. Am J Med 1987; 82: 421-426.
2) Scott JT. Asymptomatic hyperuricaemia. Br Med J 1987; 294: 987-988.
3) Roubenoff R. Gout and hyperuricemia. Rheum Dis Clin North Am 1990; 16: 539-550.
4) Brand FN, McGee DL, Kannel WB, et al. Hyperuricemia as a risk factor of coronary heart disease: the Framingham Study. Am J Epidemiol 1985; 121: 11-18.
5) Freedman DS, Williamson DF, Gunter EW, et al. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 1995; 141: 637-644.
6) Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome: unnecessary morbidity and mortality. Arthritis Rheum 1986; 29: 82-87.
7) Kabasakalian P, Kalliney S, Westcott A. Determination of uric acid in serum, with use of uricase and a tribromophenol-aminoantipyrine chromogen. Clin Chem 1973; 19: 522-524.
8) Faulds D, Sorkin EM. Felodipine: a review of the pharmacology and therapeutic use of the extended release formulation in older patients. Drugs Aging 1992;2:374-388.
9) Iimura O, Shimamoto K. Efficacy and mode of action of manidipine: a new calcium antagonist. Am Heart J 1993;125:635-641.
10) Tsunoda K, Abe K, Hagino T, et al. Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension. Am J Hypertens 1993;6:28-32.
11) van Buren M, Bijlsma JA, Boer P, et al. Natriuretic and hypotensive effect of adenosine-l blockade in essential hypertension. Hypertension 1993; 22: 728-734.
12) Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
13) Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972; 34: 187-200.
14) Fessel WJ. Renal outcomes of gout and hyperuricemia. Am J Med 1979; 67: 74-82.
15) Saggiani F, Pilati S, Targher G, Branzi P, Muggeo M, Bonora E. Serum uric acid and related factors in 500 hospitalized subjects. Metabolism 1996; 45: 1557-1561.
16) Okada M, Ueda K, Omae T, et al. The relationship of serum uric acid to hypertension and ischemic heart disease in Hisayama population, Japan. J Chron Dis 1982;35:173-178.
17) Tuomilehto J, Zimmet P, Wolf E, et al. Plasma uric acid level and its association with diabetes mellitus and some biologic parameters in a biracial population of Fiji. Am J Epidemiol 1988; 127: 321-336.
18) Kono S, Shinchi K, Imanishi K, et al. Behavioural and biological correlates of serum uric acid: a study of self-defence officials in Japan. Int J Epidemiol 1994; 23: 517-522.
19) Yano K, Rhoads GG, Kagan A. Epidemiology of serum uric acid among 8000 Japanese-American men in Hawaii. J Chron Dis 1977; 30: 171-184.
20) Goldbourt U, Medalie JH, Herman JB, et al. Serum uric acid: correlation with biochemical, anthropometric, clinical and behavioral parameters in 10,000 Israeli men. J Chron Dis 1980; 33: 435-443.
21) Cook DG, Shaper AG, Thelle DS, et al. Serum uric acid, serum glucose and diabetes: relationships in a population study. Postgrad Med J 1986; 262: 1001-1006.
22) Nicholls A, Scott JT. Effect of weight-loss on plasma and urinary levels of uric acid. Lancet 1972; 2: 1223-1224.
23) Faller J, Fox IH. Ethanol-induced hyperuricemia: evidence for increased urate production by activation of adenine nucleotide turnover. N Engl J Med 1982; 307: 1598-1602.
24) Klein R, Klein BE, Cornoni JC, et al. Serum uric acid. Its relationship to coronary heart disease risk factors and cardiovascular disease, Evans County, Georgia. Arch Intern Med 1973; 132: 401-410.
25) Zalokar J, Lellouch J, Claude JR, et al. Epidemiology of serum uric acid and gout in Frenchmen. J Chron Dis 1974; 27: 59-75.
26) Goldbourt U, Medalie JH, Herman JB, et al. Serum uric acid: correlation with biochemical, anthropometric, clinical and behavioral parameters in 10,000 Israeli men. J Chron Dis 1980; 33: 435-443.
27) Herman JB, Goldbourt U. Uric acid and diabetes: observations in a population study. Lancet 1982; 2: 240-243.
28) Rieselbach RE, Bentzel CJ, Cotlove E, et al. Uric acid excretion and renal function in the acute hyperuricemia of leukemia: pathogenesis and therapy or uric acid nephropathy. Am J Med 1964; 37: 872-884.
29) DeConti RC, Calabresi P. Use of allopurinol for prevention and control of hyperuricemia in patients with neoplastic disease. N Engl J Med 1966; 274: 481-486.
30) Cohen LF, Balow JE, Magrath IT, et al. Acute tumor lysis syndrome. A review of 37 patients with Burkitt''s lymphoma. Am J Med 1980; 68: 486-491.

Right : 1) Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia: risks and consequences in the Normative Aging Study. Am J Med 1987; 82: 421-426.
2) Scott JT. Asymptomatic hyperuricaemia. Br Med J 1987; 294: 987-988.
3) Roubenoff R. Gout and hyperuricemia. Rheum Dis Clin North Am 1990; 16: 539-550.
4) Brand FN, McGee DL, Kannel WB, et al. Hyperuricemia as a risk factor of coronary heart disease: the Framingham Study. Am J Epidemiol 1985; 121: 11-18.
5) Freedman DS, Williamson DF, Gunter EW, et al. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 1995; 141: 637-644.
6) Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome: unnecessary morbidity and mortality. Arthritis Rheum 1986; 29: 82-87.
7) Kabasakalian P, Kalliney S, Westcott A. Determination of uric acid in serum, with use of uricase and a tribromophenol-aminoantipyrine chromogen. Clin Chem 1973; 19: 522-524.
8) Faulds D, Sorkin EM. Felodipine: a review of the pharmacology and therapeutic use of the extended release formulation in older patients. Drugs Aging 1992;2:374-388.
9) Iimura O, Shimamoto K. Efficacy and mode of action of manidipine: a new calcium antagonist. Am Heart J 1993;125:635-641.
10) Tsunoda K, Abe K, Hagino T, et al. Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension. Am J Hypertens 1993;6:28-32.
11) van Buren M, Bijlsma JA, Boer P, et al. Natriuretic and hypotensive effect of adenosine-l blockade in essential hypertension. Hypertension 1993; 22: 728-734.
12) Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
13) Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972; 34: 187-200.
14) Fessel WJ. Renal outcomes of gout and hyperuricemia. Am J Med 1979; 67: 74-82.
15) Saggiani F, Pilati S, Targher G, Branzi P, Muggeo M, Bonora E. Serum uric acid and related factors in 500 hospitalized subjects. Metabolism 1996; 45: 1557-1561.
16) Okada M, Ueda K, Omae T, et al. The relationship of serum uric acid to hypertension and ischemic heart disease in Hisayama population, Japan. J Chron Dis 1982;35:173-178.
17) Tuomilehto J, Zimmet P, Wolf E, et al. Plasma uric acid level and its association with diabetes mellitus and some biologic parameters in a biracial population of Fiji. Am J Epidemiol 1988; 127: 321-336.
18) Kono S, Shinchi K, Imanishi K, et al. Behavioural and biological correlates of serum uric acid: a study of self-defence officials in Japan. Int J Epidemiol 1994; 23: 517-522.
19) Yano K, Rhoads GG, Kagan A. Epidemiology of serum uric acid among 8000 Japanese-American men in Hawaii. J Chron Dis 1977; 30: 171-184.
20) Goldbourt U, Medalie JH, Herman JB, et al. Serum uric acid: correlation with biochemical, anthropometric, clinical and behavioral parameters in 10,000 Israeli men. J Chron Dis 1980; 33: 435-443.
21) Cook DG, Shaper AG, Thelle DS, et al. Serum uric acid, serum glucose and diabetes: relationships in a population study. Postgrad Med J 1986; 262: 1001-1006.
22) Nicholls A, Scott JT. Effect of weight-loss on plasma and urinary levels of uric acid. Lancet 1972; 2: 1223-1224.
23) Faller J, Fox IH. Ethanol-induced hyperuricemia: evidence for increased urate production by activation of adenine nucleotide turnover. N Engl J Med 1982; 307: 1598-1602.
24) Klein R, Klein BE, Cornoni JC, et al. Serum uric acid. Its relationship to coronary heart disease risk factors and cardiovascular disease, Evans County, Georgia. Arch Intern Med 1973; 132: 401-410.
25) Zalokar J, Lellouch J, Claude JR, et al. Epidemiology of serum uric acid and gout in Frenchmen. J Chron Dis 1974; 27: 59-75.
26) Goldbourt U, Medalie JH, Herman JB, et al. Serum uric acid: correlation with biochemical, anthropometric, clinical and behavioral parameters in 10,000 Israeli men. J Chron Dis 1980; 33: 435-443.
27) Herman JB, Goldbourt U. Uric acid and diabetes: observations in a population study. Lancet 1982; 2: 240-243.
28) Rieselbach RE, Bentzel CJ, Cotlove E, et al. Uric acid excretion and renal function in the acute hyperuricemia of leukemia: pathogenesis and therapy or uric acid nephropathy. Am J Med 1964; 37: 872-884.
29) DeConti RC, Calabresi P. Use of allopurinol for prevention and control of hyperuricemia in patients with neoplastic disease. N Engl J Med 1966; 274: 481-486.
30) Cohen LF, Balow JE, Magrath IT, et al. Acute tumor lysis syndrome. A review of 37 patients with Burkitt's lymphoma. Am J Med 1980; 68: 486-491.

訂正日: 2006/04/07 訂正理由: - 訂正箇所: PDFファイル訂正内容: -

抄録

The Incidence of Hyperuricemia and Correlated Factors in Middle-Aged Japanese Men: Noriyuki NAKANISM, et al. Department of Social and Environmental Medicine, Course of Social Medicine, Osaka University Graduate School of Medicine F2—To identify the factors responsible for increases in serum uric acid (SUA), 1, 346 hyperuricemia-free (less than 7.5 mg/dl of SUA and no medication for hyperuricemia or hypertension) Japanese male office workers aged 30 to 53 yr were followed up for seven successive years with annual examinations, with an average period of observation of 6.4 yr with a standard deviation of 1.6 yr. Subjects who were found to have become hyperuricemic (SUA levels of 7.5 mg/dl or more) or who started medication for hyperuricemia during repeat survey were defined as incidence cases. An analysis by means of the Kaplan-Meier method showed that the incidence of hyperuricemia increased significantly with increases in the body mass index (BMI), systolic blood pressure, diastolic blood pressure, triglyceride level, SUA level, total protein level, white blood cell level, and alcohol intake. From the age-adjusted analysis with the Cox proportional hazards model, the total cholesterol level and hemoglobin A_1c (HbA_1c) level emerged as significant positive and negative factors for the incidence of hyperuricemia, respectively. Multivariate analysis, excluding the SUA level as a factor in the Cox proportional hazards model, indicated that the BMI, Log triglyceride level, white blood cell level, and alcohol intake were significantly positively associated with the incidence of hyperuricemia. On the other hand, age and the HbA_1c level were significantly inversely associated with the incidence of hyperuricemia. When the SUA level was included as a factor in the model, BMI and alcohol intake remained as independent factors. Furthermore, the white blood cell level was identified as marginally significant for the incidence of hyperuricemia (p=0.064). In conclusion, obesity and alcohol intake were determined to be independent predictors for the development of hyperuricemia. In addition, the white blood cell level may be a contributory factor.

責任著者(Corresponding author)

訂正情報

J-STAGEへの登録はこちら（無料）